Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Receivables (2016 - 2025)

OptimizeRx (OPRX) has disclosed Receivables for 16 consecutive years, with $41.7 million as the latest value for Q4 2025.

  • Quarterly Receivables rose 0.58% to $41.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $41.7 million through Dec 2025, up 0.58% year-over-year, with the annual reading at $41.7 million for FY2025, 0.58% up from the prior year.
  • Receivables hit $41.7 million in Q4 2025 for OptimizeRx, up from $35.9 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $42.3 million in Q4 2023 to a low of $757218.0 in Q3 2021.
  • Historically, Receivables has averaged $20.7 million across 5 years, with a median of $18.2 million in 2023.
  • Biggest five-year swings in Receivables: tumbled 94.32% in 2021 and later soared 794.9% in 2025.
  • Year by year, Receivables stood at $26.9 million in 2021, then decreased by 4.36% to $25.7 million in 2022, then surged by 64.46% to $42.3 million in 2023, then decreased by 2.07% to $41.5 million in 2024, then increased by 0.58% to $41.7 million in 2025.
  • Business Quant data shows Receivables for OPRX at $41.7 million in Q4 2025, $35.9 million in Q3 2025, and $37.0 million in Q2 2025.